Radiation Countermeasures: Current Status

  • Teena Haritwal Department of Radiation Genetics and Epigenetics,Institute of Nuclear Medicine and Allied Sciences, Delhi
  • Noopur Gupta Department of Radiation Genetics and Epigenetics,Institute of Nuclear Medicine and Allied Sciences, Delhi
  • Mrinalini Tiwari Department of Radiation Genetics and Epigenetics,Institute of Nuclear Medicine and Allied Sciences, Delhi
  • Sarvesh Surve Department of Radiation Genetics and Epigenetics,Institute of Nuclear Medicine and Allied Sciences, Delhi
  • Paban Kumar Agrawala Department of Radiation Genetics and Epigenetics,Institute of Nuclear Medicine and Allied Sciences, Delhi
Keywords: Ionizing radiation, Protectors, Mitigators, Therapeutics, Herbal, HDAC inhibitors

Abstract

Deleterious effects of ionising radiation leading to significant morbidity and mortality have been studied elaborately. A range of synthetic, semisynthetic and herbal compounds have been screened as radiation countermeasure agents and a number of promising radiation countermeasure agents are under development. Amifostin is the only drug which has been approved by the United State Food and Drug Administration (US-FDA), but that too for use in a defined population under strict medical supervision. Granulocyte Colony Stimulating Factor/filgrastim, γ-tocotrienol, genistein are at an advanced stage of development and are tested on higher animal models as per required norms of FDA. Herbal compounds are also considered very safe and of high value as radiation countermeasure agents owing to various properties like antioxidant, immunomodulation activity etc. Histone deacetylase inhibitors such as Trichostatin A, Diallyl sulphide, Sulforaphane are being viewed as very promising radiomitigating agents by our laboratory and active research in the same direction is going on. Infusion of hematopoietic stem cells and growth factors are in practice as potent therapeutics. This review gives an overview on various radioprotectors, radiomitigators and therapeutic agents either available or under development currently.

Author Biographies

Teena Haritwal, Department of Radiation Genetics and Epigenetics,Institute of Nuclear Medicine and Allied Sciences, Delhi

Ms Teena Haritwal is currently working as a Senior Research Fellow at Institute of Nuclear Medicine and Allied Sciences, Delhi on development of radio-mitigator with special emphasis on murine reproductive system.

Noopur Gupta, Department of Radiation Genetics and Epigenetics,Institute of Nuclear Medicine and Allied Sciences, Delhi

Ms Noopur Gupta did her MSc in Plant Biotechnology. Currently working as a Senior Research Fellow at Institute of Nuclear Medicine and Allied Sciences, Delhi on development of radio-mitigator targeting Gastro-Intestinal System.

Mrinalini Tiwari, Department of Radiation Genetics and Epigenetics,Institute of Nuclear Medicine and Allied Sciences, Delhi

Ms Mrinalini Tiwari did her MSc in Biotechnology. Currently working as a Senior Research Fellow at Institute of Nuclear Medicine and Allied Sciences, Delhi on development of radio-mitigator emphasising on DNA damage and repair.

Sarvesh Surve, Department of Radiation Genetics and Epigenetics,Institute of Nuclear Medicine and Allied Sciences, Delhi

Mr Sarvesh Surve did his MSc in Biotechnology.

Paban Kumar Agrawala, Department of Radiation Genetics and Epigenetics,Institute of Nuclear Medicine and Allied Sciences, Delhi

Dr Paban Kumar Agrawala is a PhD in Life Sciences working on the development of radiomitigators from HDAC inhibitors.

Published
2017-08-03
How to Cite
Haritwal, T., Gupta, N., Tiwari, M., Surve, S., & Agrawala, P. (2017). Radiation Countermeasures: Current Status. Defence Life Science Journal, 2(3), 278-286. https://doi.org/10.14429/dlsj.2.11675